Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic

This article was originally published in The Gray Sheet

Executive Summary

Fiscal year 1999 first quarter sales and earnings will be below company and analyst estimates, the company reports Aug. 6. Stock in Medtronic fell 5-3/4 (9.5%) points on Aug. 6 to close at 53-1/2. Complete results for the three months ended July 31 will be reported Aug. 18. The firm attributes the lower-than-anticipated results to the absence of the Kappa 700 pacemaker system and the Gem DR defibrillator system on the U.S. market, where tachyarrhythmia management sales declined 5%. Separately, a registration statement filed with the Securities & Exchange Commission covers a 12.5 mil. share offering in connection with the company's planned acquisition of Physio-Control in a pooling-of-interests transaction valued at $538 mil. ("The Gray Sheet" July 6, p. 3). Based on current stock prices, the offering would raise about $750 mil

You may also be interested in...



QUOTED. 4 December. Eric Borin.

Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.

Pfizer’s Expected 2020 COVID-19 Vaccine Production Fell By 50% After Scaleup Delays

Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.

Azurity’s Xatmep Promotional Email To Healthcare Professionals Gets Dinged By US FDA

In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel